These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Exempt, with results||2006-002692-41||Safety of AM-101 in Patients with Acute Inner Ear Tinnitus from Noise Trauma: a Dose-Finding Phase I/II Study||2008-03-15||not-yet-due|
|Reported results||2008-000132-40||Efficacy of AM 111 in Patients with Acute Sensorineural Hearing Loss: A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalation Phase II Study||2015-03-17||due-trials|
|Reported results||2008-005178-10||Efficacy of AM 101 in Patients with Acute Inner Ear Tinnitus: A Multi-Centre, Double-Blind, randomised, Placebo-Controlled, Multiple Dose, Group Comparison Phase II Study||2011-05-10||due-trials|
|Not reported||2009-009037-14||A randomised, blinded, phase IIa, placebo controlled, parallel group study to assess the efficacy, safety and tolerability of repeat doses of thymol solution 4% administered to the outer ear canal of ...||2010-05-17||due-trials|
|Completed, report not yet due||2012-004099-20||Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3 (TACTT3)||2017-12-28||not-yet-due|
|Not reported||2013-001527-39||AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) – an open-label extension to the TACTT3 study||2016-12-19||due-trials|
|Not reported||2013-002077-21||Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss||2017-09-29||due-trials|
|Reported results||2013-005587-26||Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2 (TACTT2)||2016-06-22||due-trials|
|Reported results||2013-005588-24||AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) – an open-label extension to the TACTT2 study||2017-01-19||due-trials|
|Not reported||2016-005166-58||Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT)||2017-11-28||due-trials|